Caplin Point Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Caplin Point Laboratories Ltd reported a 5.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.0%.
• Its expenses for the quarter were up by 4.2% QoQ and 8.4% YoY.
• The net profit increased 6.3% QoQ and increased 22.5% YoY.
• The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 20.25 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Caplin Point Laboratories Ltd is a pharmaceutical company that primarily focuses on manufacturing and marketing generic pharmaceuticals and branded formulations. The company operates in the pharmaceutical industry and is known for its wide range of products, which include injectables, tablets, and other pharmaceutical formulations. Caplin Point Laboratories Ltd has made a mark in the Latin American and African markets with its competitively priced products. The company is involved in both the development and distribution of pharmaceutical products, focusing on affordable healthcare solutions. As of the latest data, no recent major developments or changes in its business model have been publicly indicated.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Caplin Point Laboratories Ltd reported a total income of ₹564.41 crores. This represents a quarter-over-quarter (QoQ) increase of 5.8% from ₹533.36 crores in Q1FY26. Compared to the same quarter in the previous fiscal year (Q2FY25), where the total income was ₹503.87 crores, there is a year-over-year (YoY) growth of 12.0%. The increased revenue indicates a positive trajectory in sales or service delivery, showcasing the company's growth over both the previous quarter and the corresponding quarter of the last fiscal year.

Profitability

Caplin Point Laboratories Ltd's profitability for Q2FY26 demonstrates positive growth. The profit before tax (PBT) was ₹200.98 crores, marking a 9.0% increase QoQ from ₹184.43 crores in Q1FY26 and a 19.2% YoY increase from ₹168.56 crores in Q2FY25. After accounting for taxes, the profit after tax (PAT) amounted to ₹160.23 crores, up 6.3% QoQ from ₹150.76 crores in Q1FY26 and 22.5% YoY from ₹130.81 crores in Q2FY25. Earnings per share (EPS) also rose to ₹20.25, a slight QoQ increase of 1.1% from ₹20.03 in Q1FY26 and an 18.3% YoY increase from ₹17.12 in Q2FY25. These figures reflect the company's ability to enhance its profitability over both the previous quarter and the previous year.

Operating Metrics

The company's total expenses for Q2FY26 were reported at ₹363.43 crores, which represents a 4.2% increase QoQ from ₹348.93 crores in Q1FY26 and an 8.4% YoY increase from ₹335.31 crores in Q2FY25. The tax expense for the quarter was ₹40.77 crores, reflecting a significant QoQ increase of 21.0% from ₹33.70 crores in Q1FY26 and an 8.3% YoY increase from ₹37.65 crores in Q2FY25. These metrics indicate a rise in operational costs and tax liabilities, which align with the increased revenue and profits. The financial data provided does not include enough information to calculate additional financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, as further balance sheet and market data would be required.